{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:28:43Z","timestamp":1772166523723,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009591","name":"Ministerium f\u00fcr Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009591","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Fibroblast growth factor receptor (FGFR) 2 regulates the development of the adrenal gland in mice. In addition, FGFR2-mediated signalling has been shown to prevent apoptosis and to enhance proliferation in adrenocortical precursor cells. The activation of the Wingless\/Int-1 (WNT)\/beta catenin pathway as a key mechanism of adrenocortical tumourigenesis has been linked to FGFR2 signalling in other cell types. Therefore we hypothesised that FGFR2 expression may also play a role in adrenocortical carcinoma (ACC). We conducted a pilot study and analysed protein expression of FGFR2 in 26 ACCs using immunohistochemistry technique. Data on the\n                      <jats:italic>CTNNB1<\/jats:italic>\n                      mutation status and clinical data were correlated to the expression of FGFR2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed a high variability in FGFR2 expression between the different tumour samples. There was a subset of ACC with comparatively high nuclear expression of FGFR2. We did not find a clear association between the\n                      <jats:italic>CTNNB1<\/jats:italic>\n                      mutational status or clinical features and the FGFR2 expression. We conclude that FGFR signalling plays a role in adrenocortical carcinoma. Our data encourages further investigations of FGFR signalling in ACC, especially since new inhibitors of FGFR signalling are already entering clinical trials for the treatment of other cancer types.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-020-05110-5","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T08:02:47Z","timestamp":1591776167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-2756","authenticated-orcid":false,"given":"Matthias","family":"Haase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute I.","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Ashmawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margret","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"5110_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fcell.2015.00045","volume":"3","author":"R Lib\u00e9","year":"2015","unstructured":"Lib\u00e9 R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015;3:45.","journal-title":"Front Cell Dev Biol"},{"key":"5110_CR2","first-page":"1253","volume":"265","author":"DP Basile","year":"1993","unstructured":"Basile DP, Holzwarth MA. Basic fibroblast growth factor may mediate proliferation in the compensatory adrenal growth response. Am J Physiol. 1993;265:1253\u201361.","journal-title":"Am J Physiol"},{"key":"5110_CR3","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1210\/endo.141.9.7632","volume":"141","author":"N Boulle","year":"2000","unstructured":"Boulle N, Gicquel C, Logi\u00e9 A, Christol R, Feige JJ, Le Bouc Y. Fibroblast growth factor-2 inhibits the maturation of pro-insulin-like growth factor-II(Pro-IGF-II) and the expression of insulin-like growth factor binding protein-2(IGFBP-2) in the human adrenocortical tumor cell line NCI-H295R. Endocrinology. 2000;141:3127\u201336.","journal-title":"Endocrinology"},{"key":"5110_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1677\/joe.0.1580007","volume":"158","author":"JJ Feige","year":"1998","unstructured":"Feige JJ, Vilgrain I, Brand C, Bailly S, Souchelnitskiy S. Fine tuning of adrenocortical functions by locally produced growth factors. J Endocrinol. 1998;158:17\u20139.","journal-title":"J Endocrinol"},{"key":"5110_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1677\/JOE-06-0083","volume":"192","author":"M Haase","year":"2007","unstructured":"Haase M, Schott M, Bornstein SR, Malendowicz LK, Scherbaum WA, Willenberg HS. CITED2 is expressed in human adrenocortical cells and regulated by basic fibroblast growth factor. J Endocrinol. 2007;192:459\u201365.","journal-title":"J Endocrinol"},{"key":"5110_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/annonc\/mdt419","volume":"25","author":"R Dienstmann","year":"2014","unstructured":"Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552\u201363.","journal-title":"Ann Oncol"},{"key":"5110_CR7","first-page":"307","volume":"23","author":"Y Katoh","year":"2009","unstructured":"Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics. Int J Mol Med. 2009;23:307\u201311.","journal-title":"Int J Mol Med"},{"key":"5110_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.mce.2013.01.014","volume":"371","author":"L Guasti","year":"2013","unstructured":"Guasti L, Candy Sze WC, McKay T, Grose R, King PJ. FGF signalling through Fgfr2 isoform IIIb regulates adrenal cortex development. Mol Cell Endocrinol. 2013;371:182\u20138.","journal-title":"Mol Cell Endocrinol"},{"key":"5110_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mce.2015.06.022","volume":"413","author":"R H\u00e4fner","year":"2015","unstructured":"H\u00e4fner R, Bohnenpoll T, Rudat C, Schultheiss TM, Kispert A. Fgfr2 is required for the expansion of the early adrenocortical primordium. Mol Cell Endocrinol. 2015;413:168\u201377.","journal-title":"Mol Cell Endocrinol"},{"key":"5110_CR10","doi-asserted-by":"publisher","first-page":"16052","DOI":"10.18632\/oncotarget.14109","volume":"8","author":"YK Chae","year":"2017","unstructured":"Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8:16052\u201374.","journal-title":"Oncotarget"},{"key":"5110_CR11","doi-asserted-by":"publisher","first-page":"8610","DOI":"10.1038\/s41598-018-26799-2","volume":"8","author":"R Maharjan","year":"2018","unstructured":"Maharjan R, Backman S, \u00c5kerstr\u00f6m T, Hellman P, Bj\u00f6rklund P. Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: identification of novel mutations and correlation to survival. Sci Rep. 2018;8:8610.","journal-title":"Sci Rep"},{"key":"5110_CR12","doi-asserted-by":"publisher","first-page":"e35826","DOI":"10.1371\/journal.pone.0035826","volume":"7","author":"P Krejci","year":"2012","unstructured":"Krejci P, Aklian A, Kaucka M, Sevcikova E, Prochazkova J, Masek JK, Mikolka P, Pospisilova T, Spoustova T, Weis M, Paznekas WA, Wolf JH, Gutkind JS, Wilcox WR, Kozubik A, Jabs EW, Bryja V, Salazar L, Vesela I, Balek L. Receptor tyrosine kinases activate canonical WNT\/\u03b2-catenin signaling via MAP kinase\/LRP6 pathway and direct \u03b2-catenin phosphorylation. PLoS ONE. 2012;7:e35826.","journal-title":"PLoS ONE"},{"key":"5110_CR13","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1242\/dev.01239","volume":"131","author":"J Schmahl","year":"2004","unstructured":"Schmahl J, Kim Y, Colvin JS, Ornitz DM, Capel B. Fgf9 induces proliferation and nuclear localization of FGFR2 in Sertoli precursors during male sex determination. Development. 2004;131:3627\u201336.","journal-title":"Development"},{"key":"5110_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1210\/jc.2014-3282","volume":"100","author":"CC Juhlin","year":"2015","unstructured":"Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, B\u00e4ckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, H\u00f6\u00f6g A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab. 2015;100:493\u2013502.","journal-title":"J Clin Endocrinol Metab"},{"key":"5110_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1756-0500-4-72","volume":"4","author":"AJ Martin","year":"2011","unstructured":"Martin AJ, Grant A, Ashfield AM, Palmer CN, Baker L, Quinlan PR, Purdie CA, Thompson AM, Jordan LB, Berg JN. FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes. 2011;4:72.","journal-title":"BMC Res Notes"},{"key":"5110_CR16","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","volume":"65","author":"F Tissier","year":"2005","unstructured":"Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagner\u00e9 AM, Ren\u00e9-Corail F, Jullian E, Gicquel C, Bertagna X, Vacher-Lavenu MC, Perret C, Bertherat J. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622\u20137.","journal-title":"Cancer Res"},{"key":"5110_CR17","doi-asserted-by":"publisher","first-page":"5440","DOI":"10.18632\/oncotarget.6706","volume":"7","author":"D Ranieri","year":"2016","unstructured":"Ranieri D, Rosato B, Nanni M, Magenta A, Belleudi F, Torrisi MR. Expression of the FGFR2 mesenchymal splicing variant in epithelial cells drives epithelial-mesenchymal transition. Oncotarget. 2016;7:5440\u201360.","journal-title":"Oncotarget"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-020-05110-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T19:13:21Z","timestamp":1623266001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-05110-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5110"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-05110-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.24557\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.24557\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.24557\/v2","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was waived due to the retrospective design of this study. A significant number of the patients was not alive or was not contactable due to other reasons (loss of follow up). The study did not impose any risk to the patients. The study design excludes the possibility of identification of patients based on the anonymization of data. The study was approved by the local ethics committee of the Heinrich-Heine-University Duesseldorf (Study Number 4546).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}